ACE Inhibitors vs ARBs for Kidney Disease: Which to Choose

TL;DR

• Both ACE inhibitors and ARBs slow kidney disease progression by reducing proteinuria and intraglomerular pressure — neither class is clearly superior for renal outcomes.
• KDIGO 2024 guidelines recommend a maximally tolerated ACEI or ARB (not both) for adults with CKD and albuminuria ≥30 mg/g.
• ARBs cause significantly less dry cough and angioedema, making them the practical first-line swap when an ACEI is not tolerated.
• Dual ACEI + ARB blockade is harmful — the ONTARGET trial showed increased hyperkalemia, hypotension, and acute kidney injury with no renal benefit.
• Monitor serum potassium and creatinine within 2–4 weeks of starting or up-titrating either drug class.

Chronic kidney disease (CKD) affects roughly 10–13% of adults worldwide and remains a leading driver of cardiovascular mortality. Regardless of the underlying cause — diabetes, hypertension, glomerulonephritis — proteinuria is the single strongest modifiable predictor of renal decline. For over three decades, drugs that block the renin-angiotensin-aldosterone system (RAAS) have formed the pharmacological backbone of kidney protection. The two major RAAS-blocking classes, ACE inhibitors vs ARBs kidney disease strategies, dominate guideline recommendations, yet the question of which to choose still generates real clinical debate. This article breaks down the evidence, the practical differences, and what current guidelines actually say.

How ACE Inhibitors and ARBs Protect the Kidneys

Both drug classes interrupt the renin-angiotensin-aldosterone system, but at different points.

ACE inhibitors (angiotensin-converting enzyme inhibitors) block the enzyme that converts angiotensin I to angiotensin II. This reduces angiotensin II-mediated vasoconstriction of the efferent glomerular arteriole, lowering intraglomerular pressure and thereby reducing the mechanical stress that drives proteinuria and glomerulosclerosis. ACEIs also increase circulating bradykinin — a vasodilatory peptide — which contributes to additional blood-pressure lowering but is also responsible for the characteristic dry cough.

ARBs (angiotensin II receptor blockers) act one step downstream. They selectively block the angiotensin II type 1 (AT1) receptor, achieving a similar reduction in efferent arteriolar tone and intraglomerular pressure. Because ARBs do not inhibit ACE, bradykinin levels are not elevated, and cough rates are similar to placebo.

The net renal effect — reduced glomerular hyperfiltration, decreased proteinuria, slowed fibrosis — is mechanistically equivalent. The clinically relevant differences lie in tolerability, adverse-effect profiles, and the strength of trial data in specific populations.

Head-to-Head Evidence: Key Trials

The comparative evidence base spans several landmark randomized controlled trials.

Landmark ACEI Trials in CKD

• REIN (1997) — ramipril slowed GFR decline and reduced proteinuria in non-diabetic proteinuric nephropathy versus placebo.
• HOPE (2000) — ramipril reduced cardiovascular events in high-risk patients, with a subgroup analysis showing renal benefit in patients with mild renal insufficiency.
• Lewis Trial (1993) — captopril reduced the risk of doubling of serum creatinine by 48% in patients with type 1 diabetic nephropathy, independent of blood pressure effects.

Landmark ARB Trials in CKD

• RENAAL (2001) — losartan reduced the composite of doubling of creatinine, end-stage renal disease, or death by 16% versus placebo in type 2 diabetic nephropathy.
• IDNT (2001) — irbesartan reduced the risk of doubling of creatinine by 33% versus amlodipine and 20% versus placebo in overt diabetic nephropathy.
• IRMA-2 (2001) — irbesartan slowed progression from microalbuminuria to overt proteinuria in type 2 diabetes.

Direct Comparison: ONTARGET

The ONTARGET trial (2008) randomized 25,620 patients with vascular disease or high-risk diabetes to ramipril, telmisartan, or both. Key findings:

• Telmisartan was non-inferior to ramipril for the primary composite cardiovascular endpoint.
• Combination therapy increased adverse events — hyperkalemia, hypotensive symptoms, and renal dysfunction — without additional cardiovascular or renal benefit.
• The renal substudy showed that while combination therapy reduced proteinuria more than monotherapy, it paradoxically increased the rate of dialysis initiation and doubling of creatinine.

This trial effectively ended the dual-blockade debate and underpins the strong KDIGO recommendation against combining ACEIs and ARBs.

What KDIGO 2024 Guidelines Recommend

The KDIGO 2024 Clinical Practice Guideline for Chronic Kidney Disease provides clear, graded recommendations:

1. Start an ACEI or ARB in adults with CKD and severely increased albuminuria (≥300 mg/g, category A3), titrated to the maximum approved or maximally tolerated dose (Grade 1B).
2. Consider an ACEI or ARB in adults with CKD and moderately increased albuminuria (30–299 mg/g, category A2), particularly if diabetic (Grade 2C).
3. Do not combine an ACEI with an ARB (Grade 1B).
4. Integrate RAAS blockade with other guideline-directed therapies — specifically SGLT2 inhibitors (dapagliflozin, empagliflozin), which now carry independent evidence for CKD progression reduction (DAPA-CKD, EMPA-KIDNEY trials) and are recommended as add-on to maximally tolerated ACEI or ARB.
5. Monitor potassium and creatinine within 2–4 weeks of initiation or dose change. A rise in serum creatinine of up to 30% from baseline is expected and acceptable; rises exceeding 30% should prompt investigation.

The guidelines do not preferentially recommend ACEIs over ARBs or vice versa. The choice is left to clinical judgment based on tolerability and patient-specific factors.

Dosing and Practical Use

Titration to the maximally tolerated dose is critical — subtherapeutic dosing is one of the most common reasons for inadequate renoprotection in clinical practice.

Practical prescribing notes:

• Lisinopril vs losartan is one of the most common real-world comparisons. Both are inexpensive generics with once-daily dosing. Lisinopril has more robust trial data in heart failure (ATLAS), while losartan has the strongest CKD-specific evidence in diabetic nephropathy (RENAAL). If cost is equivalent, either is acceptable as first-line; switch to the other class if cough develops on lisinopril.
• Ramipril kidney protection evidence is particularly strong in non-diabetic proteinuric CKD (REIN trial) and in cardiovascular risk reduction (HOPE trial). Many nephrologists consider ramipril the ACEI with the strongest overall evidence profile for kidney disease.
• ARBs generally do not require dose reduction for renal impairment because most are hepatically metabolized. ACEIs, in contrast, are often renally excreted (lisinopril entirely so) and require dose adjustment in advanced CKD.
• Start low and titrate every 2–4 weeks. Document tolerability at each step — blood pressure, potassium, creatinine.

Side Effects and Monitoring

ACEI-Specific Side Effects

• Dry cough: occurs in 5–20% of patients, more common in women and individuals of East Asian descent. Caused by bradykinin accumulation in pulmonary tissue. Usually develops within weeks to months. Resolves within 1–4 weeks of discontinuation.
• Angioedema: rare (0.1–0.7%) but potentially life-threatening. Disproportionately affects Black patients (up to 3× higher incidence). Requires permanent ACEI discontinuation. If an ARB is subsequently used, monitoring during the first few doses is prudent — cross-reactivity is uncommon (<2%) but not zero.

ARB-Specific Side Effects

• Cough and angioedema rates are similar to placebo in controlled trials.
• Dizziness and orthostatic hypotension may occur at higher doses, particularly in volume-depleted patients.

Shared Side Effects (Both Classes)

• Hyperkalemia: the most important metabolic risk, particularly in patients with eGFR <30 mL/min, diabetes, or concomitant use of potassium-sparing diuretics, trimethoprim, or NSAIDs. Risk is amplified if combined with mineralocorticoid receptor antagonists (spironolactone, finerenone).
• Acute kidney injury: typically functional (hemodynamic) rather than structural. A mild creatinine rise (up to 30%) reflects reduced intraglomerular pressure and is renoprotective. Rises >30% suggest renal artery stenosis, volume depletion, or concurrent nephrotoxin exposure.
• Hypotension: more common in patients on diuretics or with heart failure. Consider holding diuretics for 24–48 hours before initiating RAAS blockade in at-risk patients.
• Teratogenicity: both ACEIs and ARBs are absolutely contraindicated in pregnancy (FDA category D/X). They cause fetal renal agenesis, oligohydramnios, and neonatal death. Women of childbearing potential must have reliable contraception, and the drugs must be stopped immediately upon confirmed pregnancy.

Monitoring schedule:

• Baseline: serum creatinine, eGFR, potassium, urinary albumin-to-creatinine ratio (uACR).
• 2–4 weeks after initiation or dose change: repeat creatinine and potassium.
• Stable patients: every 3–6 months, aligned with CKD monitoring intervals.
• After intercurrent illness (diarrhea, vomiting, dehydration): recheck creatinine and potassium promptly.

Contraindications and Drug Interactions

Special Populations

Diabetic Nephropathy

RAAS blockade is the cornerstone of renoprotection in both type 1 and type 2 diabetes:

• Type 1 diabetes with nephropathy: captopril was the first agent to demonstrate renal benefit (Lewis Trial, 1993). ACEIs are traditionally preferred in this population, though this is based on historical precedent rather than comparative data against ARBs.
• Type 2 diabetes with nephropathy: ARBs (losartan, irbesartan) have the most robust trial evidence (RENAAL, IDNT, IRMA-2). In practice, either class is acceptable. KDIGO does not differentiate between ACEIs and ARBs for diabetic kidney disease.
• Modern management now incorporates SGLT2 inhibitors (dapagliflozin, empagliflozin) and finerenone (a non-steroidal mineralocorticoid receptor antagonist) on top of maximally tolerated ACEI or ARB, based on the DAPA-CKD, EMPA-KIDNEY, FIDELIO-DKD, and FIGARO-DKD trials.

Elderly Patients (>75 Years)

• Hypotension risk is higher due to reduced baroreceptor sensitivity and concurrent polypharmacy.
• Start at the lowest dose and titrate slowly.
• Monitor for orthostatic symptoms at each visit.
• Do not withhold RAAS blockade based on age alone — the benefits of renoprotection persist in older adults with albuminuric CKD.

Black Patients

• ACEIs and ARBs tend to produce smaller blood-pressure reductions as monotherapy in Black patients, who often have lower-renin hypertension. However, the antiproteinuric and renoprotective effects are independent of blood pressure and are preserved across racial groups.
• Angioedema risk with ACEIs is higher (up to 3× relative risk); ARBs may be preferred as initial therapy in this population.
• Combination with a thiazide diuretic or calcium channel blocker improves both blood pressure control and renal outcomes.

Kidney Transplant Recipients

• RAAS blockade can be used post-transplant for proteinuria or hypertension, but calcineurin inhibitor-induced hyperkalemia complicates management.
• Monitor potassium meticulously. Some transplant centers avoid ACEIs/ARBs in the early post-transplant period due to hemodynamic vulnerability of the graft.

Patients on Dialysis

• Once patients are on maintenance hemodialysis with negligible residual renal function, the renoprotective rationale for RAAS blockade disappears.
• ACEIs and ARBs may still be used for cardiovascular risk reduction or blood pressure control, but evidence in the dialysis population is mixed. The FOSIDIAL and OCTOPUS trials did not show consistent survival benefit.

Red Flags — When to Seek Immediate Medical Attention

Stop ACEI/ARB and contact your prescriber or seek emergency care if:

• Swelling of the face, lips, tongue, or throat (angioedema) — call emergency services immediately
• Severe lightheadedness or fainting, especially after the first dose or a dose increase
• Urine output drops significantly or stops entirely
• Muscle weakness, irregular heartbeat, or tingling in extremities (symptoms of severe hyperkalemia)
• Positive pregnancy test — stop the medication immediately and inform your obstetrician

Contact your prescriber (non-urgent but important) if:

• Persistent dry cough that interferes with sleep or daily activities
• Dizziness upon standing that does not improve after a few days
• Nausea, vomiting, or diarrhea lasting >24 hours (risk of dehydration-induced AKI)
• New prescription for NSAIDs, potassium supplements, or trimethoprim-sulfamethoxazole

Frequently Asked Questions

Is lisinopril or losartan better for kidney disease?

Neither is categorically superior. Lisinopril vs losartan comparisons lack a head-to-head renal outcomes trial. Losartan has dedicated evidence in type 2 diabetic nephropathy (RENAAL), while lisinopril has broader cardiovascular trial data. KDIGO treats ACEIs and ARBs as interchangeable for CKD. The practical decision often comes down to cough tolerance — if cough develops on lisinopril, switching to losartan is standard practice.

Can I take an ACE inhibitor and an ARB together?

No. Dual RAAS blockade with an ACEI plus an ARB is explicitly discouraged by KDIGO, the AHA, and the ESC. The ONTARGET trial demonstrated that combination therapy increases hyperkalemia, hypotension, and acute kidney injury without improving renal or cardiovascular outcomes. This applies equally to combining either class with direct renin inhibitors (aliskiren).

Does ramipril protect the kidneys better than other ACE inhibitors?

Ramipril has the broadest evidence base among ACEIs — the REIN trial showed renoprotection in non-diabetic CKD, and the HOPE trial demonstrated cardiovascular benefit in high-risk patients. Whether ramipril is pharmacologically superior to other ACEIs or simply better studied is unclear. The kidney-protective effect is considered a class effect of all ACEIs, and KDIGO does not recommend one ACEI over another.

What should I do if my creatinine rises after starting an ACEI or ARB?

A creatinine rise of up to 30% from baseline is expected and actually indicates that the drug is working — it reflects reduced intraglomerular pressure. Do not stop the medication for a mild creatinine rise. If creatinine rises >30%, your prescriber should evaluate for volume depletion, concurrent nephrotoxic drugs (especially NSAIDs), or renal artery stenosis. In most cases, dose reduction or addressing the reversible cause resolves the issue.

Are ACE inhibitors or ARBs safe with an eGFR below 30?

Yes, with caveats. KDIGO supports continuing RAAS blockade in advanced CKD (eGFR 15–29 mL/min), but closer monitoring is essential — potassium checks every 1–2 weeks during titration, and prompt reassessment during intercurrent illness. Some guidelines suggest reducing the ACEI starting dose in this range. The decision to continue, dose-reduce, or stop should be made collaboratively with a nephrologist.

Should I stop my ACE inhibitor or ARB before surgery?

This remains debated. Some anesthesiologists recommend holding the drug 24 hours before major surgery to reduce intraoperative hypotension risk. Others argue that the rebound hypertension risk outweighs this concern. Discuss with your surgical and anesthesia team. The drug is typically restarted postoperatively once the patient is hemodynamically stable and adequately hydrated.

Can I take potassium supplements while on an ACEI or ARB?

Only with close monitoring. Both ACEIs and ARBs reduce aldosterone-mediated potassium excretion, raising serum potassium. Adding potassium supplements, potassium-sparing diuretics, or even high-potassium salt substitutes can push levels into dangerous territory (>5.5 mEq/L). If supplementation is needed for documented hypokalemia, your prescriber should monitor serum potassium within 1 week of starting.

What is the role of SGLT2 inhibitors alongside ACEIs or ARBs?

SGLT2 inhibitors (dapagliflozin, empagliflozin) provide additive renoprotection on top of maximally tolerated RAAS blockade. The DAPA-CKD and EMPA-KIDNEY trials showed that these agents reduce the risk of CKD progression independently of diabetes status. Current KDIGO guidelines recommend adding an SGLT2 inhibitor in patients with CKD and eGFR ≥20 mL/min. The ACEI or ARB remains the foundation; the SGLT2 inhibitor is added as a second pillar.

References

1. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events (ONTARGET). N Engl J Med. 2008;358(15):1547-1559. PMID: 18378520

2. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy (RENAAL). N Engl J Med. 2001;345(12):861-869. PMID: 11565518

3. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes (IDNT). N Engl J Med. 2001;345(12):851-860. PMID: 11565517

4. The GISEN Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy (REIN). Lancet. 1997;349(9069):1857-1863. PMID: 9217756

5. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329(20):1456-1462. PMID: 8413456

6. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314. KDIGO CKD Guideline

7. Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy (VA NEPHRON-D). N Engl J Med. 2013;369(20):1892-1903. PMID: 24206457

8. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease (DAPA-CKD). N Engl J Med. 2020;383(15):1436-1446. PMID: 32970396

9. The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease (EMPA-KIDNEY). N Engl J Med. 2023;388(2):117-127. PMID: 36331190

10. Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes (FIDELIO-DKD). N Engl J Med. 2020;383(23):2219-2229. PMID: 33264825

11. NICE. Chronic kidney disease: assessment and management. Guideline NG203. 2021 (updated 2024). nice.org.uk/guidance/ng203

About the Author

Dr. Stanislav Ozarchuk, PharmD, is a clinical pharmacist with 15 years of experience in hospital and ambulatory care settings, specializing in cardiovascular and renal pharmacotherapy. He has served as a drug information consultant for multidisciplinary nephrology teams and currently writes evidence-based medication guides for PillsCard.com to help patients and caregivers make informed decisions about their treatments.

Medical Disclaimer

This article is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment. The information provided reflects current guidelines and evidence as of the publication date but may not account for individual clinical circumstances. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Do not disregard professional medical advice or delay seeking care because of information read on this website. If you are experiencing a medical emergency, contact your local emergency services immediately.